Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
InterCure Ltd. (INCR) is an Israel-based life sciences company operating primarily in the medical cannabis industry. The company focuses on the cultivation, production, distribution, and commercialization of pharmaceutical-grade medical cannabis products, serving regulated medical markets. InterCure operates across the cannabis value chain, emphasizing compliance with stringent medical and regulatory standards and positioning itself as a premium provider in physician-prescribed cannabis therapies.
The company’s core revenue drivers are medical cannabis cultivation, branded product sales, and distribution through controlled channels. InterCure primarily serves licensed medical cannabis patients, healthcare providers, and pharmacies, with a strategic emphasis on brand-driven differentiation, quality control, and clinical credibility. Founded in 1994 as a biotechnology company, InterCure underwent a strategic transformation beginning in 2018, pivoting decisively toward the medical cannabis sector following regulatory reforms in Israel that enabled commercial-scale medical cannabis production and exports.
Business Operations
InterCure generates revenue through vertically integrated operations encompassing cultivation, manufacturing, branding, and distribution of medical cannabis products. Its primary operating segment is Medical Cannabis, which includes indoor cultivation facilities, GMP-certified manufacturing, product branding, and nationwide distribution to licensed pharmacies. The company controls advanced agricultural and pharmaceutical infrastructure designed to meet Israeli and international medical standards.
Operations are primarily concentrated in Israel, supported by proprietary cultivation technologies and centralized logistics. InterCure operates through key subsidiaries, including Canndoc Ltd., which functions as its flagship medical cannabis brand and operational arm. The company has established long-term strategic relationships with international cannabis genetics providers and pharmaceutical-focused cannabis companies, enabling access to differentiated product lines and intellectual property.
Strategic Position & Investments
InterCure’s strategic direction centers on expanding its leadership in Israel’s regulated medical cannabis market while building optionality for international growth as export frameworks evolve. Growth initiatives include capacity expansion, introduction of new medical cannabis formulations, and deepening relationships with healthcare professionals and pharmacies. The company has invested heavily in pharmaceutical-grade cultivation, quality assurance systems, and brand development.
A cornerstone of InterCure’s strategy has been strategic partnerships and licensing agreements with global cannabis companies, allowing the import and local production of internationally recognized cannabis brands. Canndoc Ltd. remains the company’s most significant subsidiary and strategic asset. InterCure is also involved in emerging areas such as data-driven patient treatment optimization and standardized medical cannabis formulations, although clinical outcome data remains limited based on public disclosures.
Geographic Footprint
InterCure’s operations are primarily based in Israel, where its headquarters, cultivation facilities, manufacturing sites, and distribution network are located. The company maintains a nationwide presence across Israeli pharmacies authorized to dispense medical cannabis, giving it broad domestic market penetration.
Internationally, InterCure has established strategic relationships and commercial linkages with partners in North America and Europe, primarily related to genetics, branding, and potential export markets. While international sales have been discussed in corporate disclosures, large-scale recurring export revenues remain limited or not clearly distinguishable based on available public sources.
Leadership & Governance
InterCure is led by an executive team with experience across healthcare, biotechnology, and regulated industries. The company emphasizes a governance philosophy centered on regulatory compliance, physician engagement, and long-term market credibility within medical cannabis.
Key executives include:
- Alexander Rabinovitch – Chief Executive Officer
- Ehud Barak – Chairman of the Board
- David Markovich – Chief Financial Officer
- Yakir Yitzhaki – Deputy CEO and Head of Operations
The leadership team has articulated a strategic vision focused on positioning InterCure as a trusted, pharmaceutical-standard medical cannabis company, prioritizing sustainable growth within regulated frameworks over rapid expansion into non-medical markets.